Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.73 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.73 |
| ▸ | ITGAL | P20701 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13894107 | 0.88 | ITGB2 (0.67) | ITGB2ICAM1ITGAL | |
| SCHEMBL879397 | 0.86 | ITGB2 (0.78) | ITGB2ICAM1ITGAL | |
| SCHEMBL15780865 | 0.86 | ITGB2 (0.69) | ITGB2ICAM1ITGAL | |
| SCHEMBL4755971 | 0.85 | ITGB2 (1.00) | ITGB2ICAM1ITGAL | |
| SCHEMBL12507169 | 0.85 | ITGB2 (0.74) | ITGB2ICAM1ITGAL | |
| SCHEMBL16851514 | 0.84 | ITGB2 (0.77) | ITGB2ICAM1ITGAL | |
| SCHEMBL4755889 | 0.84 | ITGB2 (0.81) | ITGB2ICAM1ITGAL | |
| SCHEMBL13894078 | 0.84 | ITGB2 (0.65) | ITGB2ICAM1ITGAL | |
| SCHEMBL22296811 | 0.84 | ITGB2 (0.80) | ITGB2ICAM1ITGAL | |
| SCHEMBL4755902 | 0.84 | ITGB2 (0.80) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110165229-A1 | Compositions and Methods for Treatment | SARCODE CORPORATION (US) | 2011-07-07 | — | — | US | disclosed |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165229-A1 | Compositions and Methods for Treatment | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
| US-20100092541-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | ICAM1, VCAM1, ITGAL | ITGB2 8/4885ICAM1 1/4885ITGAL 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.